HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for UroGen Pharma, maintaining a price target of $60. This suggests confidence in the company's future performance.
October 03, 2024 | 11:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for UroGen Pharma, maintaining a price target of $60. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $60 price target by HC Wainwright & Co. indicates a positive outlook on UroGen Pharma's stock. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100